• Home
  • About us
  • Our products
  • Your health
  • Responsibility
  • In the community
  • Research & development
  • Investors
  • Media centre
  • Careers
GlaxoSmithKline logo

Ozone depleting substances in manufacturing

A small proportion of the CFC used as a propellant in our Metered Dose Inhalers (MDIs) is released during the manufacturing process. We are working to eliminate use of ozone depleting substances (ODSs) in MDIs by switching to HFC and dry powder inhalers (see metered dose inhalers).

Performance

Ozone depletion potential from production (million kg CFC-11 equivalent)

Ozone depletion potential from production by business (million kg CFC-11 equivalent)

Note to ozone depletion potential charts
We report ozone depletion potential in CFC-11 equivalents as defined by the United Nations Environment Programme (UNEP) Ozone Secretariat (www.ghgprotocol.org and www.ipcc.ch)

Ozone depleting substances released from production activities
Substance Kg Factor Ozone Depletion Potential
CFC11/R11 14,658 1.000 14,658
CFC12/R12 36,317 1.000 36,317

Total ozone depletion potential from production decreased by 13% since 2004 (72% since 2001). Ozone depletion potential from production per unit sales decreased by 19% since 2004 (74% since 2001) – meaning we have beaten our 2005 target of a 50% reduction per unit sales since 2001.

As production of CFC-containing MDIs decreases, the amount of CFC lost during production also declines. We will no longer manufacture CFC-containing MDIs in the US after 2005 and in Europe after 2006. We will continue to manufacture them in Bangladesh, China, India and Pakistan until the end of 2010.


* Back to top


This section contains information in several formats:

To download PDF files you will need Adobe Reader. If you do not have it installed, it is available free from the Adobe website. PDF links on this site open in a new window.

For audio-visual content you can use either Windows Media Player or Real Player, which can be installed free from their respective websites.